Diabetic Macular Edema News and Research

RSS

Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.

CEO of pSivida to discuss new technologies in retinal drug delivery at the San Diego Ophthalmic summit

pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced that Dr. Paul Ashton, CEO, will lead a discussion on New Technologies in Retinal Drug Delivery at the 5th Annual Ophthalmic Drug Development and Delivery Summit to be held September 21-22, 2009 in San Diego.

19 Sep 2009

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD).

14 Sep 2009

Alcon to acquire ESBATech AG

Alcon (NYSE:ACL) announced today that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company. Alcon will pay ESBATech shareholders $150 million in cash at closing, plus contingent payments of up to $439 million based upon the achievement of future research and development milestones that would be expected to create value for Alcon.

14 Sep 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

Alimera Sciences' $5 million extension of Series C financing closed

Alimera Sciences, Inc., today announced that it has closed a $5 million extension of its Series C financing which was originally completed in March 2008.

28 Aug 2009

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics

iCo Therapeutics Inc. (TSX-V: ICO) today reported financial results for the quarter ended June 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

24 Aug 2009

Protease inhibitor found to aid diabetic retinopathy treatment

Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.

21 Jan 2009

Ellex Medical Lasers announces results of retina regeneration therapy

Ellex Medical Lasers has announced the six-month clinical study results for the groundbreaking treatment Retina Regeneration Therapy (Ellex 2RT) at the annual meeting of the American Academy of Ophthalmology.

10 Nov 2008

Data Safety Monitoring Board supports continuation of trial of Iluvien for diabetic macular edema

pSivida Corp. has announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change.

25 Sep 2008

Laser therapy more effective than corticosteroids in long term treatment of diabetic macular edema

A promising new drug therapy used to treat abnormal swelling in the eye - a condition called diabetic macular edema - proved less effective than traditional laser treatments in a study funded by the National Eye Institute (NEI), part of the National Institutes of Health (NIH).

29 Jul 2008

Ranibizumab therapy for diabetic eye disease shows promise

A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.

29 Apr 2008

Age-related macular degeneration patient receives investigational eye drops

An 88-year-old man at The Methodist Hospital in Houston is one of two patients in the world today to receive an investigational eye drop that may restore sight for those suffering from neovascular (wet) age-related macular degeneration, a major cause of central visual loss and one of the leading causes of blindness in people over 60 in the United States.

17 Aug 2007

Clinical trial of Ranibizumab for edema of the mAcula in diabetes

The Juvenile Diabetes Research Foundation, the world's largest charitable funder of type 1 diabetes research, announced that the Ranibizumab for Edema of the mAcula in Diabetes Phase 2 Study (READ 2) is now enrolling patients.

2 Apr 2007

New compound ruboxistaurin may decrease vision loss in diabete

A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association's journal Diabetes brings hopeful news to the 18 million people in the United States -- and millions more worldwide -- with type 1 or type 2 diabetes.

15 Jul 2005

New treatment improves visual acuity score of patients with retinitis pigmentosa

Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech’s patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.

8 May 2005

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Eli Lilly and Company's investigational compound ruboxistaurin may reduce vision loss from diabetes-induced eye disease, according to new analyses of previously reported data presented at the 2004 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology in New Orleans, La.

26 Oct 2004

Findings about diabetic eye disease may lead to improved screenings and treatment for people with diabetes

Eli Lilly and Company have announced key findings from analyses of prior study data that enhances understanding of vision loss due to diabetic retinopathy, a diabetic microvascular complication that affects an estimated 50 million people worldwide.

10 Sep 2004

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.

20 May 2004

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema, fluid buildup in the part of the eye responsible for central vision, according to a pilot study by scientists at Johns Hopkins and the National Eye Institute.

18 May 2004

Risk Assessment of Diabetic Retiopathy Improved by Screening Methods

Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.

23 Mar 2004

Diabetic Macular Edema News and Research

CEO of pSivida to discuss new technologies in retinal drug delivery at the San Diego Ophthalmic summit

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Alcon to acquire ESBATech AG

Thrombogenics issues business update and half year results

Alimera Sciences' $5 million extension of Series C financing closed

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics

Protease inhibitor found to aid diabetic retinopathy treatment

Ellex Medical Lasers announces results of retina regeneration therapy

Data Safety Monitoring Board supports continuation of trial of Iluvien for diabetic macular edema

Laser therapy more effective than corticosteroids in long term treatment of diabetic macular edema

Ranibizumab therapy for diabetic eye disease shows promise

Age-related macular degeneration patient receives investigational eye drops

Clinical trial of Ranibizumab for edema of the mAcula in diabetes

New compound ruboxistaurin may decrease vision loss in diabete

New treatment improves visual acuity score of patients with retinitis pigmentosa

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Findings about diabetic eye disease may lead to improved screenings and treatment for people with diabetes

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

Risk Assessment of Diabetic Retiopathy Improved by Screening Methods

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News